HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hegele, R. A. Articles by Leff, T. Search for Related Content PubMed PubMed Citation Articles by Hegele, R. A. Articles by Leff, T. Social Bookmarking                What's this?

PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy

¹ Robarts Research Institute, London, Ontario, Canada
² Pfizer Global Research and Development, Ann Arbor, Michigan
³ Department of Pathology and the Center for Integrative Metabolic and Endocrine Research, Wayne State University School of Medicine, Detroit, Michigan

Autosomal dominant familial partial lipodystrophy (FPLD) due to mutant LMNA encoding nuclear lamin A/C is characterized by adipose tissue repartitioning together with multiple metabolic disturbances, including insulin resistance and dyslipidemia. There is emerging evidence that some rare mutations in peroxisome proliferator-activated receptor- (PPAR-), encoded by PPARG, might be associated with human lipodystrophy. We report a three-generation Canadian kindred ascertained based upon partial lipodystrophy, with a normal LMNA gene sequence. Candidate gene sequencing showed that all four affected subjects were heterozygous for a novel TA mutation at PPARG nucleotide 1164 in exon 5 that predicted substitution of phenylalanine at codon 388 by leucine (F388L). The mutation was absent from normal family members and normal unrelated subjects, and altered a highly conserved residue within helix 8 of the predicted ligand-binding pocket of PPAR-. The mutant receptor had significantly decreased basal transcriptional activity and impaired stimulation by a synthetic ligand. The germline transmission of a transactivation-deficient mutation in PPARG suggests that autosomal dominant partial lipodystrophy is genetically heterogeneous. Our findings are consistent with the idea that mutant PPARG can underlie the partial lipodystrophy phenotype.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Kim, L.-W. Huang, K. J. Snow, V. Ablamunits, M. G. Hasham, T. H. Young, A. C. Paulk, J. E. Richardson, J. P. Affourtit, T. Shalom-Barak, et al. A mouse model of conditional lipodystrophy PNAS, October 16, 2007; 104(42): 16627 - 16632. [Abstract] [Full Text] [PDF]

				S. I. Anghel, E. Bedu, C. D. Vivier, P. Descombes, B. Desvergne, and W. Wahli Adipose Tissue Integrity as a Prerequisite for Systemic Energy Balance: A CRITICAL ROLE FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma} J. Biol. Chem., October 12, 2007; 282(41): 29946 - 29957. [Abstract] [Full Text] [PDF]

				A. Ludtke, J. Buettner, H. H-J Schmidt, and H. J Worman New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand J. Med. Genet., September 1, 2007; 44(9): e88 - e88. [Abstract] [Full Text] [PDF]

				R. A. Hegele, T. R. Joy, S. A. Al-Attar, and B. K. Rutt Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism J. Lipid Res., July 1, 2007; 48(7): 1433 - 1444. [Abstract] [Full Text] [PDF]

				A. Ludtke, J. Buettner, W. Wu, A. Muchir, A. Schroeter, S. Zinn-Justin, S. Spuler, H. H.-J. Schmidt, and H. J. Worman Peroxisome Proliferator-Activated Receptor-{gamma} C190S Mutation Causes Partial Lipodystrophy J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2248 - 2255. [Abstract] [Full Text] [PDF]

				H. Monajemi, L. Zhang, G. Li, E. H. Jeninga, H. Cao, M. Maas, C. B. Brouwer, E. Kalkhoven, E. Stroes, R. A. Hegele, et al. Familial Partial Lipodystrophy Phenotype Resulting from a Single-Base Mutation in Deoxyribonucleic Acid-Binding Domain of Peroxisome Proliferator-Activated Receptor-{gamma} J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1606 - 1612. [Abstract] [Full Text] [PDF]

				E. H. Jeninga, O. van Beekum, A. D. J. van Dijk, N. Hamers, B. I. Hendriks-Stegeman, A. M. J. J. Bonvin, R. Berger, and E. Kalkhoven Impaired Peroxisome Proliferator-Activated Receptor {gamma} Function through Mutation of a Conserved Salt Bridge (R425C) in Familial Partial Lipodystrophy Mol. Endocrinol., May 1, 2007; 21(5): 1049 - 1065. [Abstract] [Full Text] [PDF]

				G. Li and T. Leff Altered Promoter Recycling Rates Contribute to Dominant-Negative Activity of Human Peroxisome Proliferator-Activated Receptor-{gamma} Mutations Associated with Diabetes Mol. Endocrinol., April 1, 2007; 21(4): 857 - 864. [Abstract] [Full Text] [PDF]

				R. L. Boguslavsky, C. L. Stewart, and H. J. Worman Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy Hum. Mol. Genet., February 15, 2006; 15(4): 653 - 663. [Abstract] [Full Text] [PDF]

				J R Porter and T G Barrett Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and {beta} cell failure J. Med. Genet., December 1, 2005; 42(12): 893 - 902. [Abstract] [Full Text] [PDF]

				R. A. Hegele Retinoid X Receptor Heterodimers in the Metabolic Syndrome. N. Engl. J. Med., November 10, 2005; 353(19): 2088 - 2088. [Full Text] [PDF]

				R. A. Hegele and R. L. Pollex Genetic and physiological insights into the metabolic syndrome Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R663 - R669. [Abstract] [Full Text] [PDF]

				S. Vankoningsloo, M. Piens, C. Lecocq, A. Gilson, A. De Pauw, P. Renard, C. Demazy, A. Houbion, M. Raes, and T. Arnould Mitochondrial dysfunction induces triglyceride accumulation in 3T3-L1 cells: role of fatty acid {beta}-oxidation and glucose J. Lipid Res., June 1, 2005; 46(6): 1133 - 1149. [Abstract] [Full Text] [PDF]

				C. Capanni, E. Mattioli, M. Columbaro, E. Lucarelli, V. K. Parnaik, G. Novelli, M. Wehnert, V. Cenni, N. M. Maraldi, S. Squarzoni, et al. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy Hum. Mol. Genet., June 1, 2005; 14(11): 1489 - 1502. [Abstract] [Full Text] [PDF]

				B. D. Freedman, E.-J. Lee, Y. Park, and J. L. Jameson A Dominant Negative Peroxisome Proliferator-activated Receptor-{gamma} Knock-in Mouse Exhibits Features of the Metabolic Syndrome J. Biol. Chem., April 29, 2005; 280(17): 17118 - 17125. [Abstract] [Full Text] [PDF]

				R. K. Semple, A. Meirhaeghe, A. J. Vidal-Puig, J. W. R. Schwabe, D. Wiggins, G. F. Gibbons, M. Gurnell, V. K. K. Chatterjee, and S. O'Rahilly A Dominant Negative Human Peroxisome Proliferator-Activated Receptor (PPAR){alpha} Is a Constitutive Transcriptional Corepressor and Inhibits Signaling through All PPAR Isoforms Endocrinology, April 1, 2005; 146(4): 1871 - 1882. [Abstract] [Full Text] [PDF]

				C. Knouff and J. Auwerx Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology Endocr. Rev., December 1, 2004; 25(6): 899 - 918. [Abstract] [Full Text] [PDF]

				M. C. Vantyghem, P. Pigny, C. A. Maurage, N. Rouaix-Emery, T. Stojkovic, J. M. Cuisset, A. Millaire, O. Lascols, P. Vermersch, J. L. Wemeau, et al. Patients with Familial Partial Lipodystrophy of the Dunnigan Type Due to a LMNA R482W Mutation Show Muscular and Cardiac Abnormalities J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5337 - 5346. [Abstract] [Full Text] [PDF]

				K. Al-Shali, H. Cao, N. Knoers, A. R. Hermus, C. J. Tack, and R. A. Hegele A Single-Base Mutation in the Peroxisome Proliferator-Activated Receptor {gamma}4 Promoter Associated with Altered in Vitro Expression and Partial Lipodystrophy J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5655 - 5660. [Abstract] [Full Text] [PDF]

				J. Phan, M. Peterfy, and K. Reue Lipin Expression Preceding Peroxisome Proliferator-activated Receptor-{gamma} Is Critical for Adipogenesis in Vivo and in Vitro J. Biol. Chem., July 9, 2004; 279(28): 29558 - 29564. [Abstract] [Full Text] [PDF]

				M. Agostini, M. Gurnell, D. B. Savage, E. M. Wood, A. G. Smith, O. Rajanayagam, K. T. Garnes, S. H. Levinson, H. E. Xu, J. W. R. Schwabe, et al. Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor {gamma} Endocrinology, April 1, 2004; 145(4): 1527 - 1538. [Abstract] [Full Text] [PDF]

				A. Garg Acquired and Inherited Lipodystrophies N. Engl. J. Med., March 18, 2004; 350(12): 1220 - 1234. [Full Text] [PDF]

				H. Cao, E. van der Veer, M. R. Ban, A. J. G. Hanley, B. Zinman, S. B. Harris, T. K. Young, J. G. Pickering, and R. A. Hegele Promoter Polymorphism in PCK1 (Phosphoenolpyruvate Carboxykinase Gene) Associated with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 898 - 903. [Abstract] [Full Text] [PDF]

				H. Koutnikova, T.-A. Cock, M. Watanabe, S. M. Houten, M.-F. Champy, A. Dierich, and J. Auwerx Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR{gamma} hypomorphic mice PNAS, November 25, 2003; 100(24): 14457 - 14462. [Abstract] [Full Text] [PDF]

				O. Gavrilova, M. Haluzik, K. Matsusue, J. J. Cutson, L. Johnson, K. R. Dietz, C. J. Nicol, C. Vinson, F. J. Gonzalez, and M. L. Reitman Liver Peroxisome Proliferator-activated Receptor {gamma} Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass J. Biol. Chem., September 5, 2003; 278(36): 34268 - 34276. [Abstract] [Full Text] [PDF]

				M. Gurnell, D. B. Savage, V. K. K. Chatterjee, and S. O'Rahilly The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor {gamma} and Its Therapeutic Modulation J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2412 - 2421. [Abstract] [Full Text] [PDF]

				V. Simha, A. K. Agarwal, E. A. Oral, J.-P. Fryns, and A. Garg Genetic and Phenotypic Heterogeneity in Patients with Mandibuloacral Dysplasia-Associated Lipodystrophy J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2821 - 2824. [Abstract] [Full Text] [PDF]

				K. L. Herbst, L. R. Tannock, S. S. Deeb, J. Q. Purnell, J. D. Brunzell, and A. Chait Kobberling Type of Familial Partial Lipodystrophy: An underrecognized syndrome Diabetes Care, June 1, 2003; 26(6): 1819 - 1824. [Abstract] [Full Text] [PDF]

				P. M. Ridker, N. R. Cook, S. Cheng, H. A. Erlich, K. Lindpaintner, J. Plutzky, and R. Y.L. Zee Alanine for Proline Substitution in the Peroxisome Proliferator-Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 859 - 863. [Abstract] [Full Text] [PDF]